

Interleukin-15 and cancer. Some solved and many unsolved questions.

Fiore P.^{1§}, Di Matteo S.^{1§}, Tumino N.¹, Mariotti F.¹, Pietra G.^{2,3}, Ottonello S.^{4,5}, Negrini S.⁶, Bottazzi B.⁷, Moretta L.¹, Mortier E.^{8,9*} and Azzarone B.^{1*}

Supplemental References to Table 1.

Vincent M, Teppaz G, Lajoie L, Solé V, Bessard A, Maillason M, Loisel S, Béchard D, Clémenceau B, Thibault G, Garrigue-Antar L, Jacques Y, Quéméner A. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. *MAbs*. 2014 Jul-Aug;6(4):1026-37.

Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillason M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. *Int J Cancer*. 2013 Aug 1;133(3):757-65.

Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, Liu B, Zhu X, Wen J, You L, Kong L, Edwards AC, Han K, Shi S, Alter S, Sacha JB, Jeng EK, Cai W, Wong HC. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models. *Cancer Immunol Res*. 2016 Jan;4(1):49-60.

Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. *Clin Cancer Res*. 2016 Feb 1;22(3):596-608.

Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Rumfield CS, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J. The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. *Oncoimmunology*. 2018 Nov 27;8(2):e1532764.

Furuya H, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, Hokutan K, Alter S, Rhode P, Rosser CJ. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. *J Transl Med*. 2019 Jan 17;17(1):29.

Liu B, Jones M, Kong L, Noel T, Jeng EK, Shi S, England CG, Alter S, Miller JS, Cai W, Rhode PR, Wong HC. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. *Cytokine*. 2018 Jul;107:105-112.

Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. *Oncotarget*. 2016 Mar 29;7(13):16130-45.

Mathios D, Park CK, Marcus WD, Alter S, Rhode PR, Jeng EK, Wong HC, Pardoll DM, Lim M. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. *Int J Cancer*. 2016 Jan 1;138(1):187-94.

Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, Kong L, Jeng EK, Han K, Marcus WD, Rubinstein MP, Rhode PR, Wong HC. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. *Cancer Res*. 2013 May 15;73(10):3075-86.

Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Trigged NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. *Clin Cancer Res*. 2016 Feb 1;22(3):596-608.

Moga E, Cantó E, Vidal S, Juarez C, Sierra J, Briones J. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. *Exp Hematol*. 2011 Nov;39(11):1064-71.

Liu B, Kong L, Han K, Hong H, Marcus WD, Chen X, Jeng EK, Alter S, Zhu X, Rubinstein MP, Shi S, Rhode PR, Cai W, Wong HC. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses. *J Biol Chem*. 2016 Nov 11;291(46):23869-23881.

Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. *Proc Natl Acad Sci U S A*. 2018 Nov 13;115(46):E10915-E10924.

Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. *J Immunol*. 2008 Feb 15;180(4):2099-106.

Zhang M, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. *J Immunol*. 2012 Jun 15;188(12):6156-64.

Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fassò M, Allison JP, Waldmann TA. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. *Proc Natl Acad Sci U S A*. 2012 Apr 17;109(16):6187-92.

Zhao M, Luo M, Xie Y, Jiang H, Cagliero C, Li N, Ye H, Wu M, Hao S, Sun T, Yang H, Zhang M, Lin T, Lu H, Zhu J. Development of a recombinant human IL-15-sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. *Biomed Pharmacother*. 2019 Apr;112:108677.

Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. *J Immunother Cancer*. 2019 Mar 21;7(1):82.

Knudson KM, Hicks KC, Ozawa Y, Schlom J, Gameiro SR. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. *J Immunother Cancer*. 2020 Apr;8(1):e000493.